Suchergebnisse - "Tabak, Fehmi"

PubPharm (321)

41

Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey

enthalten in: Advances in therapy | 2021

von Oksuz, E. | Malhan, S. | Gonen, M. | +8

42

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases : a controlled study among hospital workers and elderly

enthalten in: Rheumatology international | 2021

von Seyahi, E. | Bakhdiyarli, G. | Oztas, M. | +9

43

Clinical Characteristics of Mild-Moderate COVID-19 Patients and Risk Factors for the Development of Pneumonia

enthalten in: Mikrobiyoloji bulteni | 2021

von Özdemir, Y. | Balkan, �. | Bayramlar, O. | +12

44

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

enthalten in: Rheumatology international | 2021

von Seyahi, E. | Bakhdiyarli, G. | Oztas, M. | +9

45

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

enthalten in: Rheumatology international | 2021

von Seyahi, E. | Bakhdiyarli, G. | Oztas, M. | +9

46

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

enthalten in: Rheumatology international | 2021

von Seyahi, E. | Bakhdiyarli, G. | Oztas, M. | +9

47

Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey : a web-based survey

enthalten in: Rheumatology international | 2021

von Yurttas, B. | Poyraz, B. | Sut, N. | +6

48

Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients : real-world data

enthalten in: International journal of STD & AIDS | 2021

von Tabak, F. | Zerdali, E. | Altuntaş, O. | +9

49

Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae

enthalten in: European journal of clinical microbiology & infectious diseases | 2021

von Balkan, I. | Alkan, M. | Aygün, G. | +11

50

Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae

enthalten in: European journal of clinical microbiology & infectious diseases | 2021

von Balkan, I. | Alkan, M. | Aygün, G. | +11